Tanabe Pharma America, Inc.

Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms

Role: lead

MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women

Role: lead

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects

Role: lead

Safety and Efficacy Study of MT-2990 in Women With Endometriosis

Role: lead

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

Role: lead

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

Role: lead

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

Role: lead

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

Role: lead

Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS

Role: lead

Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Role: lead

Safety Study of Oral Edaravone Administered in Subjects With ALS

Role: lead

Mass Balance Study With MT-8554

Role: lead

Definitive QT Study With MT-8554

Role: lead

Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

Role: lead

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

Role: lead

INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP

Role: lead

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Role: lead

Analysis of Human ALS Tissues and Registry of ALS Patients

Role: collaborator

Home-based Remote Digital Monitoring to Assess ALS Progression (Track ALS)

Role: collaborator

Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

Role: lead